TY - JOUR
T1 - White matter hyperintensities and their impact in brain structure and function in alzheimer’s disease and behavioral variant frontotemporal dementia across Latin America and the United States
T2 - a cross-sectional study
AU - Altschuler, Florencia
AU - Canziani, Verónica
AU - Fraile-Vázquez, Matías
AU - Gonzalez-Gomez, Raul
AU - Hernández, Hernán
AU - Baez, Sandra
AU - Migeot, Joaquín
AU - Fittipaldi, Sol
AU - Maito, Marcelo Adrian
AU - Legaz, Agustina
AU - Godoy, Maria Eugenia
AU - Moguilner, Sebastián
AU - Cruzat, Josephine
AU - Coronel-Oliveros, Carlos
AU - Tagliazucchi, Enzo
AU - Garcia, Hernando Santamaria
AU - Reyes, Pablo
AU - Matallana, Diana L.
AU - Avila-Funes, José Alberto
AU - Slachevsky, Andrea
AU - Behrens, María I.
AU - Custodio, Nilton
AU - Cardona, Juan Felipe
AU - Brusco, Luis Ignacio
AU - Bruno, Martin A.
AU - Ortiz, Ana L.Sosa
AU - Pina-Escudero, Stefanie D.
AU - Takada, Leonel T.
AU - Resende, Elisa de Paula Franca
AU - Possin, Katherine L.
AU - de Oliveira, Maira Okada
AU - Hu, Kun
AU - Lawlor, Brian
AU - Yokoyama, Jennifer S.
AU - Miller, Bruce
AU - Lopera, Francisco
AU - Garcia, Adolfo Martin
AU - Medel, Vicente
AU - Ibañez, Agustin
AU - Campo, Cecilia Gonzalez
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: White matter hyperintensities (WMHs) are a core manifestation of normal and pathological aging and are potentially linked to geographical differences in social and physical exposomes. Previous studies have not examined the impact of WMHs burden on neurodegeneration and cognition in healthy controls (HCs) and patients with Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD) across geographic regions. This study addressed this gap by assessing the impact of WMHs burden on participants with and without dementia from Latin America (LA) and the United States (US). Methods: The study comprised 994 participants, including HCs (n = 402), AD (n = 359), and bvFTD subjects (n = 233) from LA and the US. WMHs and their association with grey matter (GM) atrophy, assessed through GM volume and cortical thickness, were evaluated and compared among groups (HCs, AD, and bvFTD) in LA and the US using a voxel-wise brain imaging approach (p < 0.05 family-wise error-corrected for multiple comparisons, minimum cluster size = 50 voxels). Multiple regressions analysis were employed to examine geographic differences in WMHs burden, WMHs-GM associations, and the effect of WMHs on cognitive performance, as assessed by the Mini-Mental State examination. Results: In the LA cohort only, higher WMHs load was associated with greater GM atrophy across all groups (HCs, AD, bvFTD), with a specific neurodegenerative pattern involving orbitofrontal, cingulate, and temporal areas. HCs from LA showed a greater WMHs load than their US counterparts, and this effect was dependent on GM atrophy. Finally, WMHs burden negatively impacted cognitive performance in dementia subjects, with a greater effect observed in bvFTD subjects from the US. Conclusion: WMHs have a more pronounced impact on neurodegeneration across the LA cohort, with a worse impact on HCs, which also show higher WMHs burden than their US counterparts. This could increase the risk of developing dementia. Moreover, WMHs burden differentially impacts cognition, with a greater negative effect observed in bvFTD subjects from the US. These findings highlight geographic variations in WMHs-related conditions, offering valuable insights for tailored future research.
AB - Background: White matter hyperintensities (WMHs) are a core manifestation of normal and pathological aging and are potentially linked to geographical differences in social and physical exposomes. Previous studies have not examined the impact of WMHs burden on neurodegeneration and cognition in healthy controls (HCs) and patients with Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD) across geographic regions. This study addressed this gap by assessing the impact of WMHs burden on participants with and without dementia from Latin America (LA) and the United States (US). Methods: The study comprised 994 participants, including HCs (n = 402), AD (n = 359), and bvFTD subjects (n = 233) from LA and the US. WMHs and their association with grey matter (GM) atrophy, assessed through GM volume and cortical thickness, were evaluated and compared among groups (HCs, AD, and bvFTD) in LA and the US using a voxel-wise brain imaging approach (p < 0.05 family-wise error-corrected for multiple comparisons, minimum cluster size = 50 voxels). Multiple regressions analysis were employed to examine geographic differences in WMHs burden, WMHs-GM associations, and the effect of WMHs on cognitive performance, as assessed by the Mini-Mental State examination. Results: In the LA cohort only, higher WMHs load was associated with greater GM atrophy across all groups (HCs, AD, bvFTD), with a specific neurodegenerative pattern involving orbitofrontal, cingulate, and temporal areas. HCs from LA showed a greater WMHs load than their US counterparts, and this effect was dependent on GM atrophy. Finally, WMHs burden negatively impacted cognitive performance in dementia subjects, with a greater effect observed in bvFTD subjects from the US. Conclusion: WMHs have a more pronounced impact on neurodegeneration across the LA cohort, with a worse impact on HCs, which also show higher WMHs burden than their US counterparts. This could increase the risk of developing dementia. Moreover, WMHs burden differentially impacts cognition, with a greater negative effect observed in bvFTD subjects from the US. These findings highlight geographic variations in WMHs-related conditions, offering valuable insights for tailored future research.
KW - Alzheimer’s disease
KW - Frontotemporal dementia
KW - Latin America
KW - MRI
KW - White Matter Hyperintensities
UR - https://www.scopus.com/pages/publications/105013203168
U2 - 10.1186/s13195-025-01832-5
DO - 10.1186/s13195-025-01832-5
M3 - Article
C2 - 40797280
AN - SCOPUS:105013203168
SN - 1758-9193
VL - 17
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 188
ER -